Sam Quigley is a seasoned technology executive and founder with 17 years of experience, currently CEO of Kicho Inc in New York leading a multi-modality program to develop near-term therapies for dup15q syndrome and validating an ASO knockdown of UBE3A. He combines product, security and operations expertise gained at Square and Wesabe with strategic advisory work through Emerose Advisory Services and board service at the Dup15q Alliance. That blend of fintech-grade operational rigor and strategic biotech focus helps him translate complex scientific and regulatory challenges into practical development roadmaps. He holds a BA from the University of Chicago and spent time studying at Humboldt‑Universität zu Berlin, underscoring a global, interdisciplinary approach.
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.